March 06th, 2017

MedDay Boosts its Research Capabilities with Profilomic Acquisition
Read more

September 28th, 2016

MedDay Strengthens its Board with Two Senior Non-Executive Directors
Read more

September 14th, 2016

Positive Preclinical Data with MD1003 (high dose pharmaceutical grade biotin) in X-Linked Adrenoleukodystrophy to be presented at European Committee for Treatment and Research in Multiple Sclerosis 2016
Read more

September 02nd, 2016

MedDay Announces Publication of MD1003 Phase IIb/III Study in the Multiple Sclerosis Journal
Read more

May 25th, 2016

MedDay attends European Academy of Neurology 2016 and presents extension phase results of the MS-SPI trial
Read more

April 27th, 2016

MedDay appoints Catherine Moukheibir as Chairman of its Board of Directors
Read more

April 08th, 2016

MedDay Secures €34 Million ($38.5M) New Funding
Read more

December 01st, 2015

MedDay provides update on MS-ON study of MD1003
Read more

October 07th, 2015

MedDay reports additional positive analyses of its pivotal study with MD1003 in patients with primary and secondary Progressive Multiple Sclerosis
Read more

June 19th, 2015

MedDay reports additional positive data of its pivotal Phase III study with MD1003 in patients with Progressive Multiple Sclerosis
Read more

June 17th, 2015

MedDay and DSM announce a partnership to produce pharmaceutical grade D-Biotin to treat progressive multiple sclerosis
Read more

April 27th, 2015

MedDay to webcast results of its pivotal Phase III study of MD1003 in patients with Progressive Multiple Sclerosis
Read more